Galectin-1 in Pancreatic Ductal Adenocarcinoma: Bridging Tumor Biology, Immune Evasion, and Therapeutic Opportunities
-
Published:2023-10-24
Issue:21
Volume:24
Page:15500
-
ISSN:1422-0067
-
Container-title:International Journal of Molecular Sciences
-
language:en
-
Short-container-title:IJMS
Author:
Bogut Ana1, Stojanovic Bojan23ORCID, Jovanovic Marina4, Dimitrijevic Stojanovic Milica5, Gajovic Nevena6, Stojanovic Bojana S.7, Balovic Goran2, Jovanovic Milan8, Lazovic Aleksandar3ORCID, Mirovic Milos9, Jurisevic Milena10, Jovanovic Ivan6ORCID, Mladenovic Violeta4
Affiliation:
1. City Medical Emergency Department, 11000 Belgrade, Serbia 2. Department of Surgery, Faculty of Medical Sciences, University of Kragujevac, 34000 Kragujevac, Serbia 3. Department of General Surgery, University Clinical Center Kragujevac, 34000 Kragujevac, Serbia 4. Department of Internal Medicine, Faculty of Medical Sciences, University of Kragujevac, 34000 Kragujevac, Serbia 5. Department of Pathology, Faculty of Medical Sciences, University of Kragujevac, 34000 Kragujevac, Serbia 6. Center for Molecular Medicine and Stem Cell Research, Faculty of Medical Sciences, University of Kragujevac, 34000 Kragujevac, Serbia 7. Department of Pathophysiology, Faculty of Medical Sciences, University of Kragujevac, 34000 Kragujevac, Serbia 8. Department of Abdominal Surgery, Military Medical Academy, 11000 Belgrade, Serbia 9. Department of Surgery, General Hospital of Kotor, 85330 Kotor, Montenegro 10. Department of Clinical Pharmacy, Faculty of Medical Sciences, University of Kragujevac, 34000 Kragujevac, Serbia
Abstract
Pancreatic Ductal Adenocarcinoma (PDAC) remains one of the most challenging malignancies to treat, with a complex interplay of molecular pathways contributing to its aggressive nature. Galectin-1 (Gal-1), a member of the galectin family, has emerged as a pivotal player in the PDAC microenvironment, influencing various aspects from tumor growth and angiogenesis to immune modulation. This review provides a comprehensive overview of the multifaceted role of Galectin-1 in PDAC. We delve into its contributions to tumor stroma remodeling, angiogenesis, metabolic reprogramming, and potential implications for therapeutic interventions. The challenges associated with targeting Gal-1 are discussed, given its pleiotropic functions and complexities in different cellular conditions. Additionally, the promising prospects of Gal-1 inhibition, including the utilization of nanotechnology and theranostics, are highlighted. By integrating recent findings and shedding light on the intricacies of Gal-1’s involvement in PDAC, this review aims to provide insights that could guide future research and therapeutic strategies.
Funder
the Faculty of Medical Sciences at the University of Kragujevac, Serbia the Ministry of Science, Technological Development, and Innovation of the Republic of Serbia
Subject
Inorganic Chemistry,Organic Chemistry,Physical and Theoretical Chemistry,Computer Science Applications,Spectroscopy,Molecular Biology,General Medicine,Catalysis
Reference162 articles.
1. Ushio, J., Kanno, A., Ikeda, E., Ando, K., Nagai, H., Miwata, T., Kawasaki, Y., Tada, Y., Yokoyama, K., and Numao, N. (2021). Pancreatic Ductal Adenocarcinoma: Epidemiology and Risk Factors. Diagnostics, 11. 2. Lafond, M., Lambin, T., Drainville, R.A., Dupré, A., Pioche, M., Melodelima, D., and Lafon, C. (2022). Pancreatic Ductal Adenocarcinoma: Current and Emerging Therapeutic Uses of Focused Ultrasound. Cancers, 14. 3. Adamska, A., Domenichini, A., and Falasca, M. (2017). Pancreatic Ductal Adenocarcinoma: Current and Evolving Therapies. Int. J. Mol. Sci., 18. 4. Pancreatic ductal adenocarcinoma: Treatment hurdles, tumor microenvironment and immunotherapy;Sarantis;World J. Gastrointest. Oncol.,2020 5. Kruger, D., Lahoud, N., Yako, Y.Y., Devar, J., and Smith, M. (2022). Pancreatic ductal adenocarcinoma: Prognostic indicators of advanced disease. PLoS ONE, 17.
|
|